Adaptive response of resistant cancer cells to chemotherapy

Despite advances in cancer therapeutics and the integration of personalized medicine, the development of chemoresistance in many patients remains a significant contributing factor to cancer mortality. Upon treatment with chemotherapeutics, the disruption of homeostasis in cancer cells triggers the adaptive response which has emerged as a key resistance mechanism. In this review, we summarize the mechanistic studies investigating the three major components of the adaptive response, autophagy, endoplasmic reticulum (ER) stress signaling, and senescence, in response to cancer chemotherapy. We will discuss the development of potential cancer therapeutic strategies in the context of these adaptive resistance mechanisms, with the goal of stimulating research that may facilitate the development of effective cancer therapy.     

Left ventricular assist device implants in patients on extracorporeal membrane oxygenation: do we need cardiopulmonary bypass?

Open in a separate window OBJECTIVESImplanting a durable left ventricular assist device (LVAD) in a patient on extracorporeal life support (ECLS) is challenging. The goal of this study was to compare the results of patients from a European registry who had a durable LVAD implanted with or without transition from ECLS to cardiopulmonary bypass (CPB).METHODSA total of 531 patients on ECLS support who had an LVAD implant between January 2010 and August 2018 were analysed; after 1:1 propensity score matching, we identified and compared 175 patients in each group.RESULTSThe duration of preoperative ECLS was 7 [standard deviation (SD) 6] vs 7 (SD 6) days in patients with or without CPB (P = 0.984). The surgical time was longer in the CPB group [285 (SD 72) vs 209 [SD 75] min; P ≤ 0.001). The postoperative chest tube output was comparable [1513 (SD 1311) vs 1390 (SD 1121) ml; P = 0.3]. However, re-exploration for bleeding was necessary in 41% vs 29% of patients with or without CPB (P = 0.01) and a significantly higher number of packed red blood cells and fresh frozen plasma [8 (SD 8) vs 6 (SD 4) units; P = 0.001 and 6 (SD 7) vs 5 (SD 5) units; P = 0.03] were administered to patients operated on with CPB. A postoperative mechanical right ventricular support device was necessary in 50% vs 41% of patients (P = 0.08). The stroke rate was not significantly different (P 0.99). No difference in survival was observed.CONCLUSIONSOmitting CPB for an LVAD implant in patients on ECLS is safe and results in shorter operating time, less re-exploration for bleeding and fewer blood products. However, no survival benefit is observed.     

An immune-sympathetic neuron communication axis guides adipose tissue browning in cancer-associated cachexia

Cancer-associated cachexia (CAC) is a hypermetabolic syndrome characterized by unintended weight loss due to the atrophy of adipose tissue and skeletal muscle. A phenotypic switch from white to beige adipocytes, a phenomenon called browning, accelerates CAC by increasing the dissipation of energy as heat. Addressing the mechanisms of white adipose tissue (WAT) browning in CAC, we now show that cachexigenic tumors activate type 2 immunity in cachectic WAT, generating a neuroprotective environment that increases peripheral sympathetic activity. Increased sympathetic activation, in turn, results in increased neuronal catecholamine synthesis and secretion, β-adrenergic activation of adipocytes, and induction of WAT browning. Two genetic mouse models validated this progression of events. 1) Interleukin-4 receptor deficiency impeded the alternative activation of macrophages, reduced sympathetic activity, and restrained WAT browning, and 2) reduced catecholamine synthesis in peripheral dopamine β-hydroxylase (DBH)–deficient mice prevented cancer-induced WAT browning and adipose atrophy. Targeting the intraadipose macrophage-sympathetic neuron cross-talk represents a promising therapeutic approach to ameliorate cachexia in cancer patients.

Cancer-associated cachexia (CAC) is an energy balance disorder causing unintended loss of body weight due to depletion of white adipose tissue (WAT) and skeletal muscle. This multiorgan and multifactorial syndrome affects up to 80% of cancer patients and is responsible for more than 20% of cancer-associated deaths (1). CAC impedes the effectiveness of anticancer therapies and drastically lowers patients’ quality of life (2).A long list of tumor-borne, often proinflammatory factors, including interleukin-6 (IL-6) (3), parathyroid hormone–related protein (PTHrP) (4), leukemia inhibitory factor (LIF) (5), zinc α-glycoprotein (6), or growth differentiation factor-15 (GDF-15) (7), trigger CAC in mouse models. However, the signaling cascades and catabolic mechanisms that lead to adipose- and muscle tissue wasting remain insufficiently understood (8, 9). IL-6 and PTHrP are among the best studied of these “cachexokines.” Their presence or absence is decisive for the development of CAC in cancer patients and animal models (4, 10–13). Thus, treatment with neutralizing antibodies against IL-6, the IL-6 receptor, or PTHrP ameliorates CAC in various mouse models of CAC (3, 4, 14, 15).CAC-associated WAT atrophy results from a metabolic switch toward decreased lipid synthesis and excessive degradation of lipid stores via enhanced triglyceride degradation (lipolysis) (9, 16). Induced lipolysis is observed in both humans and mice with CAC (17, 18). The absence of metabolic lipases at least partially ameliorates cachexia in murine cancer models (19). The metabolic or catabolic fates of lipolytic products, namely fatty acids (FAs) and glycerol, have not been fully clarified. These may provide energy and/or biosynthetic substrates for cancer cells to promote tumor growth or can be reesterified in WAT, creating an adenosine-triphosphate (ATP)-consuming futile metabolic cycle. Both of these pathways would contribute to the eventual loss of WAT during CAC (20).Another important catabolic pathway in CAC involves the direct oxidation of FAs and glycerol in adipose tissue. This process is promoted by the conversion of white to beige adipocytes called “WAT browning.” During WAT browning, adipocytes adopt a multilocular lipid droplet morphology; express genes that are typical for brown adipocytes, such as uncoupling protein-1 (UCP-1); exhibit elevated substrate oxidation rates; and dissipate energy as heat (21). WAT browning occurs in carcinogen-induced cancer models and genetically engineered mouse models as well as syngeneic and xenogeneic transplant models of murine cancers (3, 4, 22) and depends on the presence of cachexokines. WAT browning also occurs in humans suffering CAC or severe burn trauma (3, 23–25), but the cellular and molecular mechanisms underlying catabolic WAT remodeling in CAC remain unclear.Here, we demonstrate that a macrophage-sympathetic neuron signaling axis generates a high β-adrenergic tone resulting in beige adipogenesis, increased lipid degradation, and WAT atrophy in murine models of CAC. This mechanism triggering hypermetabolism in CAC may offer targets for prevention or treatment of the disease.     

Eating Disorder Day Programs: Is There a Best Format?

The use of a Day Program (DP) format (i.e., intensive daily treatment with no overnight admission) has been shown to be an effective treatment for eating disorders (EDs). The disadvantages, however, include higher cost than outpatient treatment (including costs of meals and staff), greater disruption to patients’ lives, and the use of a highly structured and strict schedule that may interrupt the development of patients’ autonomy in taking responsibility for their recovery. This study investigated whether reducing costs of a DP and the disruption to patients’ lives, and increasing opportunity to develop autonomy, impacted clinical outcomes. Three sequential DP formats were compared in the current study: Format 1 was the most expensive (provision of supported dinners three times/week and extended staff hours); Format 2 included only one dinner/week and provision of a take-home meal. Both formats gave greater support to patients who were not progressing well (i.e., extended admission and extensive support from staff when experiencing feelings of suicidality or self-harm). Format 3 did not provide this greater support but established pre-determined admission lengths and required the patient to step out of the program temporarily when feeling suicidal. Fifty-six patients were included in the analyses: 45% were underweight (body mass index (BMI) < 18.5), 96.4% were female, 63% were given a primary diagnosis of anorexia nervosa (or atypical anorexia nervosa), and mean age was 25.57 years. Clinical outcomes were assessed using self-reported measures of disordered eating, psychosocial impairment, and negative mood, but BMI was recorded by staff. Over admission, 4- and 8-week post-admission, and discharge there were no significant differences between any of the clinical outcomes across the three formats. We can tentatively conclude that decreasing costs and increasing the opportunities for autonomy did not negatively impact patient outcomes, but future research should seek to replicate these results in other and larger populations that allow conclusions to be drawn for different eating disorder diagnostic groups.     

Bioactive Glasses in Periodontal Regeneration: Existing Strategies and Future Prospects—A Literature Review

The present review deals with bioactive glasses (BGs), a class of biomaterials renowned for their osteoinductive and osteoconductive capabilities, and thus widely used in tissue engineering, i.e., for the repair and replacement of damaged or missing bone. In particular, the paper deals with applications in periodontal regeneration, with a special focus on in vitro, in vivo and clinical studies. The study reviewed eligible publications, identified on the basis of inclusion/exclusion criteria, over a ranged time of fifteen years (from 1 January 2006 to 31 March 2021). While there are many papers dealing with in vitro tests, only a few have reported in vivo (in animal) research, or even clinical trials. Regardless, BGs seem to be an adequate choice as grafts in periodontal regeneration.     

Anti-inflammatory therapeutic approaches to reduce acute atherosclerotic complications

Cardiovascular diseases, including atherosclerosis and the dreaded complication myocardial infarction, represent the major cause of death in western countries. It is now generally accepted that chemokines tightly control and modulate all the events which lead to initiation and progression of cardiovascular diseases, making them very attractive therapeutic targets for the pharmaceutical industry. Various studies showed until now the effects of antagonizing/ neutralizing chemokines or blocking chemokine receptors on cardiovascular pathology. The modulation of the CCL2/CCR2, CCL5/CCR1-CCR5, CXCL12/CXCR4 pathways by preventing receptor--ligand interaction, chemokine-glycosaminoglycan interaction, heteromerization, or interfering with the signaling pathways has proven to have high potential in future drug development. However, while trying to understand the effects of individual chemokines, the biologic consequences of multiple and concomitant chemokine expression on leukocyte migration and function should be taken into account as well. Therefore, many aspects should be considered and carefully scrutinized, when devising therapeutic strategies.